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Abstract
Background Anastomotic ulcers (AUs) after Roux-en-Y gas-
tric bypass (RYGB) occur in up to 16 % of patients. In an
international survey among members of the International Fed-
eration for the Surgery of Obesity and Metabolic Disorders
(IFSO), current preventative and therapeutic strategies in AU
were analyzed.
Methods An Internet-based survey was performed.
Results One hundred eighty-nine surgeons completed the sur-
vey. Preoperative screening for Helicobacter pylori is per-
formed by 65 %. Eighty-eight percent of them prophylactical-
ly prescribe antacids for 3 months after surgery (interquartile
range (IQR) 1–6). In case of AU, 99 % of participants opt for
proton pump inhibitors (PPIs) either alone (60 %) or in combi-
nation with sucralfate (39 %). After ulcer resolution, 52 %
continue PPI for 6 (3–6)months. In case of AU recurrence,
56% continue with conservative treatment. In contrast, 41 % of
them favor a renewal of the gastrojejunal anastomosis either
combined with truncal vagotomy (18 %) or with gastric rem-
nant resection (13 %), and only 2 % choose to resect both
gastric pouch and gastric remnant with subsequent reconstruc-
tion by esophagojejunostomy. In case of recurrence after surgi-
cal revision, 46 % of participants opt again for a conservative
approach, while 36% chose to redo the gastrojejunostomy once
again.
Conclusions The majority of bariatric surgeons recommend
preoperative screening and eradication of H. pylori as well as
prophylactic use of PPI. If an AU is diagnosed, the role of PPI as
a first-line treatment seems to be undisputed. However, dosage
and duration of therapy remain unclear. In refractoryAU, there is
no consensus among bariatric surgeons whether conservative
treatment or surgical revision should be performed.
Keywords Roux-en-Y gastric bypass .Metabolic surgery .
Bariatricsurgery .Anastomoticulcer .Marginalulcer .Obesity
Introduction/Purpose
Roux-en-Y gastric bypass (RYGB) has become the gold stan-
dard among all applied bariatric procedures. In the bariatric
outcome longitudinal database of the American Society of
Metabolic and Bariatric Surgery containing 57,918 cases of
bariatric surgery, RYGB accounts for 55 % of all procedures
[1]. When compared with sleeve gastrectomy and gastric
banding, RYGB provides the most enduring and effective
long-term weight loss and reduction of obesity-associated
comorbidities [2].
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However, long-term complications do occur after RYGB
and include events such as internal hernias [3] or micronutri-
ent deficiencies [4]. In addition, the gastrojejunostomy has
been shown to be susceptible to anastomotic ulcers (AUs).
The underlying mechanisms are not entirely clear, but reduced
local blood flow, anastomotic tension, and/or Helicobacter
pylori infection may play a role [5-7]. Furthermore, the
gastrojejunostomy is not reached by the alkaline fluid secreted
by glands of the duodenum as the latter is excluded from the
nutrient flow after RYGB. Therefore, the gastrojejunal anas-
tomosis may be exposed to the undiluted acidic juice pro-
duced by the gastric pouch, subsequently leading to AU
development [8]. The incidence of AU—also known as mar-
ginal ulcers—of the gastrojejunostomy after RYGB varies
between 0.6 and 16 % [2, 9-11].
The clinical appearance of an AU ranges from asymptom-
atic to incapacitating pain, lack of appetite, abnormal weight
loss, or nausea and vomiting. Furthermore, due to chronic
occult bleeding, AU may cause anemia in as many as
10.2 % of patients after RYGB [12].
Prevention and management of AU after RYGB is still a
matter of debate. Proton pump inhibitors (PPIs) are an effi-
cient option for the prevention and treatment of peptic ulcers.
However, despite the preventative use of treatment-dose PPIs,
AU may still occur in up to 16 % of post-RYGB patients [2,
9-11]. Interestingly, AUmay even occur after successful med-
ical H. pylori eradication prior to surgery as Rasmussen et al.
demonstrated that preoperative H. pylori infection, although
adequately treated, was twice as common among patients who
had an AU (32 %) as among those who did not (12 %) [6].
Nevertheless, the management of AU consists of eliminating
known risk factors of peptic ulcers. Treatment with antacids
and elimination of NSAIDs is effective in 68 to 88 % of cases
[7, 13, 14].
Despite the best conservative therapy efforts, one third of
patients will need surgical revision for therapy refractory or
recurring AU [7, 14, 15]. The rationale behind surgical revi-
sion is the correction of technical risk factors for AU including
large gastric pouches, vertically oriented pouches [16],
gastrogastric fistulas [17], or local ischemia caused by anas-
tomotic tension [5].
Evidence-based guidelines or data from randomized con-
trolled trials on the management of AU are lacking. The aim
of this survey was therefore to determine if there is a consen-
sus among expert bariatric surgeons on preventative and ther-
apeutic strategies against AU after RYGB surgery.
Material and Methods
An Internet-based survey was sent directly by electronic mail
to members of the International Federation for the Surgery of
Obesity and Metabolic Disorders (IFSO), a federation of 46
national associations of bariatric surgeons. The survey
consisted of 20 multiple choice questions and could be com-
pleted in less than 5min. Onemonth later, the presidents of the
national societies for bariatric surgery of Argentina, Australia,
New Zealand, Belgium, Bolivia, Brazil, Chile, Columbia,
Costa Rica, Czech Republic, Egypt, Finland, France, Germa-
ny, Greece, Guatemala, Hungary, Iceland, India, Israel, Italy,
Japan, Kuwait, Lithuania, Mexico, Panama, Paraguay, Peru,
Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia,
Serbia, Singapore, Slovenia, South Africa, Spain, Sweden,
Switzerland, Taiwan, Turkey, Ukraine, United Arab Emirates,
UK, USA, Canada, as well as Venezuela were also asked to
issue the online poll among their members. The survey was
open between 14 March and 3 September 2011.
Statistical Analysis
Data were collected in a study database using Excel™ (ver-
sion 12.0, 2007, Microsoft Switzerland, Wallisellen, Switzer-
land). Descriptive statistics was performed using GraphPad™
Prism version 5.00 for Windows (GraphPad™ Software, San
Diego, California, USA). Data are presented as median (inter-
quartile range) as not otherwise stated. The chi-squared test
was used as appropriate. The level of significance was set at
p <0.05.
Results
Experience of Participating Bariatric Surgeons
Of the 189 participants who completed the survey, 81 %
reported to have performed more than 50 RYGB operations
(Table 1).
Operative Details for RYGB
To date, the majority of surveyed bariatric surgeons perform
their RYGB operations laparoscopically. In most cases (81 %,
n =153), either a circular (n =63) or linear stapler (n =90) is
used to fashion the gastrojejunostomy (Table 1). Only 19 %
(n =36) of the participants prefer to hand sew the
gastrojejunostomy, of which most (n =30) use resorbable,
and only a minority (n =6) uses nonresorbable suture material.
Thirty two percent (n =20) of surgeons using a circular
stapler additionally oversew the anastomosis either with re-
sorbable (n =16) or nonresorbable suture material (n =4). In
contrast, linear anastomoses are more frequently oversewn
(60 %, n =54; p =0.009) using resorbable material in most
of the cases (n =45). Preferences for alimentary limb lengths
are summarized in Table 1.
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Onset
In the experience, 28 % (n =52) of survey participants expect
the onset of AU to lie within the first 3 months after surgery.
All others expect AU to arise later than 3 months or even after
more than a year postoperatively [48 % (n =90) and 25% (n =
47), respectively]. The time of AU onset does not correlate
with the reported operative experience of the participating
surgeons or the preferred anastomotic technique.
Etiology
The participants were asked to name the most important
surgical and nonsurgical risk factor for the development of
an AU in their experience. The responses are shown in
Table 2.
Prevention
While 65 % (n =123) of survey participants reported to screen
their patients for presence of H. pylori before RYGB, 35 %
(n =66) reported to omit H. pylori screening. Of those who
perform preoperativeH. pylori screening, the vast majority of
98 % (n =121) performs an eradication therapy if screening
reveals a H. pylori infection; only 2 % (n =2) of survey
responders do not eradicate in such a case. No participant
would opt for a gastric remnant resection in a H. pylori-
positive patient.
Prophylactic therapy is prescribed by 88 % (n =166) after
RYGB operation, 91 % (n =151) of which prefer PPI. Dosage
and choice of agents used are summarized in Table 3.
Prophylactic medication is prescribed for a period of 1 month
postoperatively for 25 % (n =42), 3 months for 37 % (n =62),
6 months for 28 % (n =47), more than 6 months for 4 % (n =
7), or lifelong for 5 % (n =8) of the participants. The median
duration of prophylaxis is 3 months (interquartile range (IQR)
1–6).
Treatment of Primary AU
Primary AU was defined as the first occurrence of ulceration
at the level of the gastrojejunostomy. In case of primary AU,
99 % of participants favor a conservative approach. Sixty
percent of participants use PPI, 32 % a combination of PPI
and sucralfate, and 6 % a triple combination of PPI, H2
blocker, and sucralfate. Less frequently, H2 blockers alone
or in combination with sucralfate are used (Fig. 1). Forty-nine
percent (n =93) of participants using a first-line medical ther-
apy continue treatment until ulcer resolution is demonstrated
by endoscopy. Others continue medical therapy either for a
Table 1 Experience of surgeons and operative details for RYGB, n =189
% (n) of participants
Experience (number of RYGB)
<50 19 (36)
50–200 33 (63)
>200 48 (90)
Approach
Laparoscopic 91 (172)
Open 9 (17)
Technique of gastroenterostomy
Circular stapler 33 (63)
Linear stapler 48 (90)
Hand sewn 19 (36)
Length of alimentary limb (cm)
<100 7 (14)
100 42 (80)
150 43 (82)
>150 7 (13)
Table 2 Single most important surgical and nonsurgical risk factor for
AU after RYGB, n =189
% (n) of participants
Surgical risk factors
Tissue ischemia 33 (63)
Pouch size 22 (41)
Foreign bodies (sutures, staples) 19 (36)
Acid vertically oriented pouch 15 (29)
Tension on anastomosis 6 (12)
Staple line dehiscence/gastrogastric fistula 4 (8)
Nonsurgical risk factors
Smoking 46 (86)
NSAID use 29 (55)
Lack of PPI use 16 (30)
Helicobacter pylori 7 (14)
Alcohol consumption 2 (4)
Table 3 Prophylactic antacid after RYGB, n=166
% (n) of participants
PPI
Prophylactic dosage 45 (75)
Therapeutic dosage 43 (72)
Prophylactic dosage+sucralfate 1 (2)
Therapeutic dosage+sucralfate 1 (2)
H2 blocker
Prophylactic dosage 1 (2)
Therapeutic dosage 4 (6)
Sucralfate alone 1 (1)
Others 4 (6)
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fixed period of 3 months (31 %, n =58), while 20 % continue
for up to 2 years (n =37).
After AU healing, 52 % (n =99) of all participants, who
treated an ulcer conservatively, continue medical therapy for a
median of 6 months (IQR 3–6) to prevent ulcer recurrence.
Seventy-eight percent (n =77) use PPI alone, while 19 % (n =
19) choose a combination of PPI and sucralfate. Again, H2
blockers alone or in combination with sucralfate are only
rarely employed. The participating surgeons expected conser-
vative treatment to be successful in 79 % of cases within
3 months (IQR 65–83 %).
Treatment for Refractory AU
Refractory AU was defined as persistence after initial conser-
vative treatment. In case of refractory AU, 56 % (n =105) of
participants continue with the conservative approach and con-
sider surgery only if complications such as perforation, bleed-
ing, or obstruction occur. However, 41 % (n =77) choose to
resect and redo the gastrojejunostomy. Of the latter, 18 % (n =
14) add a truncal vagotomy, and another 13 % (n =10) resect
the gastric remnant. Esophagojejunostomy and RYGB rever-
sal are only rarely performed (Fig. 2a). Of note, there is a
strong correlation between surgical experience and choice of
therapy. While 51 % (n =46) of surgeons with more than 200
RYGB operations under their belt would treat refractory AU
surgically, surgeons with less RYGB experience prefer a
conservative approach (64 %, n =63, p =0.041).
Treatment for Recurrent AU After Surgical Therapy
Recurrent AU was defined as AU reoccurrence after surgical
therapy. In case of recurrent AU, 46% (n=87) of all participants
would choose a conservative treatment again, whereas 36% (n=
68) would prefer resection and subsequent redo of the
gastrojejunostomy. Of the latter, 41 % (n=28) would add a
truncal vagotomy and 25 % (n=17) a gastric remnant resection.
Another 9 % (n=17) reported to carry out a gastric pouch and
gastric remnant resectionwith subsequent esophagojejunostomy.
The remaining 6 % (n =12) would choose RYGB reversal
(Fig. 2b).
Discussion
The real incidence of AU after RYGB is still unclear. Most
studies including large patient numbers do not provide useful
insights regarding the occurrence of this specific complication
[18, 19]. So far, up to 16 % of RYGB patients have been
reported to develop an AU at their gastrojejunostomy [10,
14-16]. However, high level evidence and guidelines on pre-
vention and management of AU do currently not exist. Using
an international survey, this study sets out the common clinical
practice of 189 bariatric surgeons, 81 % of which have per-
formed more than 50 RYGB procedures. The heterogeneity of
answers in this international survey among expert bariatric
surgeons suggests that a consensus on the best treatment of
refractory AU is missing.
According to the literature, 60 % of AUs develop within
6 months after RYGB. However, they can occur up to 5 years
postoperatively [11, 20]. However, there was no agreement on
the time of AU onset after RYGB among the participants of
our survey: 25 % of participants reported AU to occur within
the first three postoperative months, 50 % between 3 months
and 1 year after surgery, and 25 % even after more than 1 year
postoperatively.
Numerous mechanisms underlying the development of AU
are currently discussed in the literature and can be divided into
surgical and nonsurgical risk factors. Concerning surgical risk
Fig. 1 Conservative therapy for AU, n =189
Fig. 2 Therapy in case of a refractory AU and b recurrent AU after
surgical revision, n=189
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factors, small-vessel ischemia and anastomotic tension are
regarded as the most important causes [7]. Less relevant
contributing factors are persistent acidity in a large gastric
pouch [21] and the use of nonabsorbable sutures to reinforce
a circularly stapled gastrojejunostomy [22, 23]. In contrast, the
technique used to fashion the gastrojejunostomy (hand sewn
vs. linear vs. circular) was not found to have an impact on AU
development [24].
Among the nonsurgical risk factors, especially smoking as
well as NSAID intake and H. pylori status are associated with
an increased risk for AU and refractory ulcer occurrence [20,
25, 26]. Accordingly, the results of our survey corroborate the
multifactorial etiology of AU as well as the variability of
importance ascribed to the single factors by bariatric surgeons
(Table 1).
While it may be difficult for physicians to influence
smoking habits as well as joint pain due to arthritis, requiring
NSAID use, H. pylori can be easily eradicated prior to sur-
gery. Indeed, AU occurs more frequently inH. pylori-positive
patients. However, it has been questioned whether preopera-
tive H. pylori eradication can lower the risk for AU develop-
ment since H. pylori-positive patients were found to have an
increased AU risk even if eradication was performed. Damage
to the mucosal barrier has been proposed as the underlying
mechanism [6, 27]. Our survey indicated that, before surgery,
the majority of bariatric surgeons routinely screen for
H. pylori and consequently perform eradication when posi-
tive. This practice seems reasonable since H. pylori testing
and eradication is simple, inexpensive, and effective [28].
Beyond that, H. pylori is a strong risk factor for peptic ulcer
development irrespective of bariatric surgery. Therefore, the
vast majority of bariatric surgeons prescribe antacids after
RYGB either at prophylactic or therapeutic dosage. However,
there is no consensus on the duration of such therapy.
In principal, AU after RYGB can be treated either conser-
vatively or surgically. The published success rate of conser-
vative therapy ranges between 68 and 88 % [7, 13, 14] which
corresponds to the estimated success rate of 79 % in our
survey. Accordingly, conservative treatment was the first
choice of our participants in the case of AU diagnosis. Hereby,
the majority of bariatric surgeons employ PPI as the first-line
and single treatment (Fig. 1). Importantly, there was no con-
sensus on the duration of therapy and whether therapy should
be continued after AU resolution. Furthermore, the correct
dosage and the need for combination of different acid-
reducing agents remain unclear.
Refractory AU after RYGB represents a clinical and ther-
apeutic challenge. Surgical options are various and include
redoing of the gastrojejunostomy combined with pouch
resizing. In a cohort study dating back to 1984, it was shown
that redoing of the gastrojejunostomy was a successful treat-
ment in up to 87 % of cases. However, in the same study,
gastrogastric fistulas were identified as the underlying cause
of AUs in 72 % [7]. As gastrogastric fistulas are rare nowa-
days, the relevance of the reported high success rate is ques-
tionable. Other options are reduction of acid production by
truncal vagotomy or gastric remnant resection, pouch resec-
tion with subsequent esophagojejunostomy, and RYGB rever-
sal. The latter offers the possibility of building a new anasto-
mosis in healthy, untouched, and well-vascularized tissue
[29]. Although feasible, RYGB reversal has not been shown
to be an effective AU treatment [30, 31].
Our survey revealed that two thirds of those surgeons with
less than 200 procedures in their pocket opt for another
conservative treatment in the case of refractory ulcer. In con-
trast, half of the bariatric surgeons with more than 200 proce-
dures seem to prefer a surgical approach. Among those, most
consider resection and redoing of the gastrojejunostomy as the
procedure of choice. If surgical therapy fails and AU reoccurs,
measures of the last resort are truncal vagotomy and gastric
remnant resection. Our survey suggests a clear correlation
between surgical experience and preferred therapy—the more
experienced a bariatric surgeon, the more often he chooses a
surgical approach to treat refractory AU. Whether an aggres-
sive surgical strategy to treat refractory AU is more effective
than a conservative approach is unclear and needs to be tested
in future studies.
In conclusion, there is no consensus for the prevention and
management of primary or refractory anastomotic ulcer, and
no recommendations can be drawn from the available litera-
ture. Given the increasing numbers of bariatric procedures
performed worldwide, multicenter prospective studies are
desperately needed to define strategies to prevent and treat
this painful and unresolved condition after RYGB.
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